SRSD107 is a long-acting investigational Factor XI siRNA anticoagulant being co-developed for thromboembolic disorders. Clinical communications report first patient dosing in a global randomized Phase 2 trial for venous thromboembolism prevention after total knee arthroplasty, following Phase 1 evidence of sustained FXI suppression. It is not approved for marketing.
CRISPR Therapeutics reported a Q4 2025 loss of $1.37 per share, missing estimates, with revenues of $0.9 million falling short of expectations. The company's partner Vertex recorded $54 million in Casgevy sales for the quarter, with regulatory submissions for pediatric label expansion planned for early 2026.
The FDA has issued draft guidance that may speed approval pathways for rare disease therapies using genome editing technologies, potentially benefiting CRISPR Therapeutics' pipeline of six clinical-stage candidates.
Switzerland-based CRISPR Therapeutics stands to benefit from increased Casgevy sales following partner Vertex Pharmaceuticals' fourth-quarter results, with five additional gene-editing therapies in clinical trials targeting larger patient populations.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07318155 |
A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease |
RECRUITING | PHASE2 |
| NCT07140523 |
A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA |
RECRUITING | PHASE2 |
| NCT06116617 |
A Phase 1 Study to Evaluate the Safety, Tolerability, PK/PD of SRSD107 in Healthy Participants |
COMPLETED | PHASE1 |
